2024
Complete vs. Incomplete Consolidative Radiotherapy in Patients with Extensive-Stage Small Cell Lung Cancer
Ninia J, Verma N, Laird J, Hayman T, Knowlton C, Peters G, Campbell A, Housri N, Feghali K, de Jong D, Park H. Complete vs. Incomplete Consolidative Radiotherapy in Patients with Extensive-Stage Small Cell Lung Cancer. International Journal Of Radiation Oncology • Biology • Physics 2024, 120: e51. DOI: 10.1016/j.ijrobp.2024.07.1890.Peer-Reviewed Original ResearchExtensive-stage small cell lung cancerProgression-free survivalSmall cell lung cancerOverall survivalCell lung cancerOligometastatic diseaseChemo-immunotherapyLung cancerSuperior progression-free survivalMedian follow-up timePatients treated with CCSites of disease involvementConsolidative thoracic radiotherapyAssociated with improved outcomesChemotherapy-based treatmentStratified Cox proportional hazard regressionsLog-rank testCox proportional hazards regressionDisease burdenTime of diagnosisKaplan-Meier estimatesProportional hazards regressionConsolidation radiotherapyPolymetastatic diseaseOligometastatic patientsRethinking the use of germline CHEK2 mutation as a marker for PARP inhibitor sensitivity
Hayman T. Rethinking the use of germline CHEK2 mutation as a marker for PARP inhibitor sensitivity. JNCI Cancer Spectrum 2024, 8: pkae045. PMID: 38950525, PMCID: PMC11216723, DOI: 10.1093/jncics/pkae045.Peer-Reviewed Original ResearchRadioresistant Pulmonary Oligometastatic and Oligoprogressive Lesions From Nonlung Primaries: Impact of Histology and Dose-Fractionation on Local Control After Radiation Therapy
Verma N, Laird J, Moore N, Hayman T, Housri N, Peters G, Knowlton C, Jairam V, Campbell A, Park H. Radioresistant Pulmonary Oligometastatic and Oligoprogressive Lesions From Nonlung Primaries: Impact of Histology and Dose-Fractionation on Local Control After Radiation Therapy. Advances In Radiation Oncology 2024, 9: 101500. PMID: 38699671, PMCID: PMC11063223, DOI: 10.1016/j.adro.2024.101500.Peer-Reviewed Original ResearchLocal recurrence-free survivalNon-lung primaryAssociated with higher local recurrence-free survivalProgression-free survivalBiologically effective doseLocal controlRadioresistant metastasesOverall survivalPulmonary metastasesPrimary cancerColorectal carcinomaAssociated with superior local controlMultivariate analysisPatients treated with radiotherapyRisk of local recurrenceMedian follow-up timeMultivariable Cox proportional hazards regressionInferior local controlMedian total doseSuperior local controlAssociated with decreased riskImpact of histologyMetastasis-free survivalRecurrence-free survivalLocal failureDose-volume Predictors of Radiation Pneumonitis Following Thoracic Hypofractionated Radiotherapy
Sasse A, Oh P, Saeed N, Yang D, Hayman T, Knowlton C, Peters G, Campbell A, Laird J, Housri N, Park H. Dose-volume Predictors of Radiation Pneumonitis Following Thoracic Hypofractionated Radiotherapy. International Journal Of Radiation Oncology • Biology • Physics 2024, 118: e5. DOI: 10.1016/j.ijrobp.2023.10.054.Peer-Reviewed Original ResearchHypofractionated radiation therapyRisk of gradeUltra-central tumoursRadiation pneumonitisLung V20Lung V5Central tumorsMultivariable logistic regression analysisSingle health care systemDose-volume predictorsDosimetric risk factorsGrade 5 toxicitySimilar local controlDose-fractionation regimensProbability of gradeProximal tracheobronchial treeLogistic regression analysisMATERIAL/METHODSHealth care systemPrimary endpointOverall survivalHypofractionated radiotherapyMultivariable analysisLung doseThoracic tumorsDosimetric Factors Associated with Esophagitis Following Hypofractionated Radiotherapy to the Thorax
Sasse, Oh P, Saeed N, Yang D, Peters G, Hayman T, Housri N, Laird J, Campbell A, Knowlton C, Park H. Dosimetric Factors Associated with Esophagitis Following Hypofractionated Radiotherapy to the Thorax. International Journal Of Radiation Oncology • Biology • Physics 2024, 118: e7-e8. DOI: 10.1016/j.ijrobp.2023.10.059.Peer-Reviewed Original ResearchHypofractionated radiation therapyTotal patientsOverall survivalLocal controlUltra-central lung tumorsMultivariable logistic regression analysisSignificant differencesComparable local controlGrade 3 esophagitisRisk of gradeCases of gradeProbability of gradeLogistic regression analysisMATERIAL/METHODSMean esophagus doseSingle healthcare systemEsophagus DmaxPrimary endpointHypofractionated radiotherapyDosimetric factorsMultivariable analysisEsophagus doseThoracic tumorsDosimetric variablesClinical trials
2023
Iron homeostasis governs erythroid phenotype in polycythemia vera
Bennett C, Jackson V, Pettikiriarachchi A, Hayman T, Schaeper U, Moir-Meyer G, Fielding K, Ataide R, Clucas D, Baldi A, Garnham A, Li-Wai-Suen C, Loughran S, Baxter E, Green A, Alexander W, Bahlo M, Burbury K, Ng A, Pasricha S. Iron homeostasis governs erythroid phenotype in polycythemia vera. Blood 2023, 141: 3199-3214. PMID: 36928379, PMCID: PMC10646816, DOI: 10.1182/blood.2022016779.Peer-Reviewed Original ResearchConceptsGenome-wide association studiesIron homeostasisErythroid phenotypePolycythemia veraRegulator of systemic iron homeostasisGenetic dissectionAssociation studiesSystemic iron homeostasisUK Biobank dataHFE variantsErythroid diseaseMouse model of PVExpression of hepcidinBiobank dataLife-threatening thrombotic eventsActivating mutationsHepcidin expressionPathophysiology of PVPhenotypeHomeostasisMyeloproliferative neoplasmsThrombotic eventsHepcidin upregulationTherapeutic strategiesInflammatory cytokines
2021
Zinc Supplementation with or without Additional Micronutrients Does Not Affect Peripheral Blood Gene Expression or Serum Cytokine Level in Bangladeshi Children
Hayman T, Hickey P, Amann-Zalcenstein D, Bennett C, Ataide R, Sthity R, Khandaker A, Islam K, Stracke K, Yassi N, Watson R, Long J, Westcott J, Krebs N, King J, Black R, Islam M, McDonald C, Pasricha S. Zinc Supplementation with or without Additional Micronutrients Does Not Affect Peripheral Blood Gene Expression or Serum Cytokine Level in Bangladeshi Children. Nutrients 2021, 13: 3516. PMID: 34684517, PMCID: PMC8541127, DOI: 10.3390/nu13103516.Peer-Reviewed Original ResearchConceptsPeripheral blood gene expressionMultiple micronutrient powdersBlood gene expressionZinc supplementationZinc interventionCytokine levelsCommunity-based efficacy trialDispersible tabletsImpact of zinc supplementationEffect of zinc supplementationSerum cytokine levelsGene expressionPreventive zinc supplementationDetect cytokine profilesSensitive multiplex assayMonths of agePlacebo powderCytokine profileImmune profilePeripheral bloodCytokine signatureHome fortificationCytokine concentrationsMicronutrient powderZinc deficiencySTING enhances cell death through regulation of reactive oxygen species and DNA damage
Hayman TJ, Baro M, MacNeil T, Phoomak C, Aung TN, Cui W, Leach K, Iyer R, Challa S, Sandoval-Schaefer T, Burtness BA, Rimm DL, Contessa JN. STING enhances cell death through regulation of reactive oxygen species and DNA damage. Nature Communications 2021, 12: 2327. PMID: 33875663, PMCID: PMC8055995, DOI: 10.1038/s41467-021-22572-8.Peer-Reviewed Original ResearchThe translocon-associated protein (TRAP) complex regulates quality control of N-linked glycosylation during ER stress
Phoomak C, Cui W, Hayman TJ, Yu SH, Zhao P, Wells L, Steet R, Contessa JN. The translocon-associated protein (TRAP) complex regulates quality control of N-linked glycosylation during ER stress. Science Advances 2021, 7: eabc6364. PMID: 33523898, PMCID: PMC7810369, DOI: 10.1126/sciadv.abc6364.Peer-Reviewed Original ResearchTranslocon-associated proteinN-glycosylationER stressER glycoprotein quality controlTranslocon-associated protein complexEndoplasmic reticulum (ER) homeostasisAberrant N-glycosylationGlycoprotein quality controlER chaperone BiPFluorescence-based strategyProtein complexesPosttranslational modificationsChaperone BiPTRAP complexGlycosylation defectsConditions of stressRegulatory roleTranscriptional signatureIndividual cellsDownstream ERProtein levelsSubunitsSSR3GlycosylationCells
2019
Whole Genome CRISPR-Cas9 Screen Identifies STING as a Determinant of Intrinsic Radiosensitivity in Head and Neck Squamous Cell Carcinoma
Hayman T, Baro M, Cui W, Contessa J. Whole Genome CRISPR-Cas9 Screen Identifies STING as a Determinant of Intrinsic Radiosensitivity in Head and Neck Squamous Cell Carcinoma. International Journal Of Radiation Oncology • Biology • Physics 2019, 105: s77-s78. DOI: 10.1016/j.ijrobp.2019.06.538.Peer-Reviewed Original ResearchRIPLET, and not TRIM25, is required for endogenous RIG‐I‐dependent antiviral responses
Hayman T, Hsu A, Kolesnik T, Dagley L, Willemsen J, Tate M, Baker P, Kershaw N, Kedzierski L, Webb A, Wark P, Kedzierska K, Masters S, Belz G, Binder M, Hansbro P, Nicola N, Nicholson S. RIPLET, and not TRIM25, is required for endogenous RIG‐I‐dependent antiviral responses. Immunology And Cell Biology 2019, 97: 840-852. PMID: 31335993, DOI: 10.1111/imcb.12284.Peer-Reviewed Original ResearchConceptsRetinoic acid-inducible gene IRetinoic acid-inducible gene-I signalingPattern recognition receptorsInfluenza A virusRIG-I activationIII interferonsRecognition receptorsTripartite motif-containing 25Host antiviral defenseImmune signaling cascadesSusceptible to IAV infectionIFN responseInfluenza B virusIFN-stimulated genesHost cell pattern recognition receptorsHuman cell linesUpregulation of IFN-stimulated genesRIG-I.Gene IInnate immune systemRipletAntiviral defenseRIG-ITRIM25Production of type I
2018
CDKN2A Copy Number Loss Is an Independent Prognostic Factor in HPV-Negative Head and Neck Squamous Cell Carcinoma
Chen WS, Bindra RS, Mo A, Hayman T, Husain Z, Contessa JN, Gaffney SG, Townsend JP, Yu JB. CDKN2A Copy Number Loss Is an Independent Prognostic Factor in HPV-Negative Head and Neck Squamous Cell Carcinoma. Frontiers In Oncology 2018, 8: 95. PMID: 29670856, PMCID: PMC5893829, DOI: 10.3389/fonc.2018.00095.Peer-Reviewed Original ResearchDisease-free survivalNeck squamous cell carcinomaSquamous cell carcinomaOverall survivalHPV-negative HNSCCPrognostic factorsCell carcinomaPoor survivalLoss groupCDKN2A mRNAMedian disease-free survivalP16 expressionCopy number lossNumber lossMedian overall survivalReceipt of chemotherapyIndependent prognostic factorUseful prognostic factorHPV-negative headHigh p16 expressionProtein expression levelsHPV infectionCancer Genome AtlasBetter prognosisMultivariable analysis
2017
Increasing Utilization of Stereotactic Radiation Therapy as a Component of Initial Therapy in Metastatic Non–small Cell Lung Cancer
Hayman T, Bledsoe T, Corso C, Lester-Coll N, Park H, Decker R. Increasing Utilization of Stereotactic Radiation Therapy as a Component of Initial Therapy in Metastatic Non–small Cell Lung Cancer. International Journal Of Radiation Oncology • Biology • Physics 2017, 99: e459. DOI: 10.1016/j.ijrobp.2017.06.1702.Peer-Reviewed Original Research(S032) Investigating CDKN2A Copy Number Loss in HPV- and HPV+ Head and Neck Cancer: A Demonstration of Integrated Genomic and Clinical Analyses Using TCGA
Chen W, Bindra R, Mo A, Hayman T, Husain Z, Contessa J, Yu J. (S032) Investigating CDKN2A Copy Number Loss in HPV- and HPV+ Head and Neck Cancer: A Demonstration of Integrated Genomic and Clinical Analyses Using TCGA. International Journal Of Radiation Oncology • Biology • Physics 2017, 98: e10. DOI: 10.1016/j.ijrobp.2017.02.068.Peer-Reviewed Original ResearchCDKN2A copy number loss in HPV- and HPV+ head and neck cancer to indicate poor prognosis: An integrated genomic and clinical TCGA analysis.
Chen W, Bindra R, Mo A, Hayman T, Husain Z, Contessa J, Gaffney S, Townsend J, Yu J. CDKN2A copy number loss in HPV- and HPV+ head and neck cancer to indicate poor prognosis: An integrated genomic and clinical TCGA analysis. Journal Of Clinical Oncology 2017, 35: 6060-6060. DOI: 10.1200/jco.2017.35.15_suppl.6060.Peer-Reviewed Original ResearchCopy number lossNumber lossP16 protein expression levelsDisease-free survivalTumor suppressor proteinMedian disease-free survivalMedian overall survivalOverall survivalGene transcriptionSuppressor proteinCDKN2A mRNAProtein expression levelsGenomic groupsCopy number ratioCancer Genome Atlas (TCGA) headGenomic measurementsHPV statusPoor prognosisNeck cancerExpression levelsLoss groupTCGA analysisProtein expressionP16 protein expressionCDKN2A
2016
Receptor Tyrosine Kinases as Targets for Enhancing Tumor Radiosensitivity
Hayman T, Contessa J. Receptor Tyrosine Kinases as Targets for Enhancing Tumor Radiosensitivity. Cancer Drug Discovery And Development 2016, 35-55. DOI: 10.1007/978-3-319-40854-5_2.Peer-Reviewed Original ResearchReceptor tyrosine kinasesTumor radiosensitivityCombination of radiotherapyTyrosine kinaseMost solid tumorsField of oncologyClinical findingsClinical prognosisMaintenance/progressionIGF-1RRadiation therapyClinical investigationAforementioned receptorsSolid tumorsC-MetModest responseTherapyRadiation oncologyOncologyCancer therapyRadiotherapyAttractive targetRadiosensitivityCellular responsesAgents
2015
Outcomes of resected pancreatic cancer in patients age ≥70
Hayman T, Strom T, Springett G, Balducci L, Hoffe S, Meredith K, Hodul P, Malafa M, Shridhar R. Outcomes of resected pancreatic cancer in patients age ≥70. Journal Of Gastrointestinal Oncology 2015, 6: 498-504. PMID: 26487943, PMCID: PMC4570916, DOI: 10.3978/j.issn.2078-6891.2015.038.Peer-Reviewed Original ResearchOutcomes of patientsAdjuvant chemoradiationOverall survivalCA19-9Patient agePancreatic cancerMultivariate analysisMedian patient ageUpfront surgical resectionPancreatic cancer patientsNeoadjuvant therapyPrimary endpointNodal statusSurgical resectionYounger patientsYear OSCancer patientsPancreatic carcinomaPatientsChemoradiationMortalitySignificant correlationOutcomesCancerMonths
2014
Pancreatic Cancer Outcomes in Resected Age ≥ 70 Patients Are Comparable to Younger Patients
Hayman T, Strom T, Springett G, Balducci L, Hoffe S, Meredith K, Malafa M, Shridhar R. Pancreatic Cancer Outcomes in Resected Age ≥ 70 Patients Are Comparable to Younger Patients. International Journal Of Radiation Oncology • Biology • Physics 2014, 90: s361. DOI: 10.1016/j.ijrobp.2014.05.1172.Peer-Reviewed Original ResearchThe ATP-Competitive mTOR Inhibitor INK128 Enhances In Vitro and In Vivo Radiosensitivity of Pancreatic Carcinoma Cells
Hayman T, Wahba A, Rath B, Bae H, Kramp T, Shankavaram U, Camphausen K, Tofilon P. The ATP-Competitive mTOR Inhibitor INK128 Enhances In Vitro and In Vivo Radiosensitivity of Pancreatic Carcinoma Cells. Clinical Cancer Research 2014, 20: 110-119. PMID: 24198241, PMCID: PMC3947297, DOI: 10.1158/1078-0432.ccr-13-2136.Peer-Reviewed Original ResearchConceptsCap-complex formationGene translationPancreatic carcinoma cellsMTOR activityPancreatic carcinoma cell linesCell linesDNA double-strand breaksATP-competitive mTOR inhibitorsCarcinoma cellsΓH2AX fociCarcinoma cell linesPolysome-bound mRNADouble-strand breaksRadiation-induced γH2AX fociAberrant mTOR activityComplex formationDNA repairFibroblast cell lineMicroarray analysisRegulatory roleINK128Normal fibroblast cell lineMTOR inhibitionVivo radiosensitivityClonogenic survival
2013
The mTORC1/mTORC2 inhibitor AZD2014 enhances the radiosensitivity of glioblastoma stem-like cells
Kahn J, Hayman T, Jamal M, Rath B, Kramp T, Camphausen K, Tofilon P. The mTORC1/mTORC2 inhibitor AZD2014 enhances the radiosensitivity of glioblastoma stem-like cells. Neuro-Oncology 2013, 16: 29-37. PMID: 24311635, PMCID: PMC3870843, DOI: 10.1093/neuonc/not139.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsApoptosisBenzamidesBrain NeoplasmsCell CycleCell ProliferationDNA Breaks, Double-StrandedDNA RepairFemaleFluorescent Antibody TechniqueGlioblastomaHistonesHumansMechanistic Target of Rapamycin Complex 1Mechanistic Target of Rapamycin Complex 2MiceMice, NudeMorpholinesMultiprotein ComplexesNeoplastic Stem CellsProtein Kinase InhibitorsPyrimidinesRadiation-Sensitizing AgentsTOR Serine-Threonine KinasesTumor Cells, CulturedXenograft Model Antitumor AssaysX-Ray TherapyConceptsGBM stem-like cellsDual mTORC1/2 inhibitorStem-like cellsOrthotopic xenograftsMTORC1/2 inhibitorsPrimary treatment modalityΓH2AX fociRadiation-induced γH2AX fociGlioblastoma stem-like cellsTreatment modalitiesClonogenic survival analysisGBM therapyMTOR inhibitorsSurvival analysisGSC cell linesClonogenic assayMammalian targetVivo responseAZD2014GlioblastomaIndividual treatmentRadiosensitivityCell linesXenograftsImmunoblot analysis